Caracemide

Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity[1][2].

Product Specifications

CAS Number

[81424-67-1]

Product Name Alternative

NSC-253272

UNSPSC

12352211

Hazard Statement

H302, H312, H315, H319, H332, H335

Target

Bacterial; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/caracemide.html

Purity

95.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(N(OC(NC)=O)C(NC)=O)=O

Molecular Formula

C6H11N3O4

Molecular Weight

189.17

Precautions

H302, H312, H315, H319, H332, H335

References & Citations

[1]Larsen IK, et al. Caracemide, a site-specific irreversible inhibitor of protein R1 of Escherichia coli ribonucleotide reductase. J Biol Chem. 1992 Jun 25;267 (18) :12627-31.|[2]Slatter JG, et al. Studies on the metabolic fate of caracemide, an experimental antitumor agent, in the rat. Evidence for the release of methyl isocyanate in vivo. Chem Res Toxicol. 1993 May-Jun;6 (3) :335-40.